What is Panacea Life Sciences Holdings Price-to-Operating-Cash-Flow?
As of today (2024-05-31), Panacea Life Sciences Holdings's share price is $0.14839.
Panacea Life Sciences Holdings's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.09. Hence, Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 4 years, Panacea Life Sciences Holdings's highest Price-to-Operating-Cash-Flow Ratio was 0.03. The lowest was 0.00. And the median was 0.00.
Panacea Life Sciences Holdings's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was $-0.02.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.09.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 35.90% per year.
During the past 4 years, Panacea Life Sciences Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was 35.90% per year. The lowest was 35.90% per year. And the median was 35.90% per year.
Panacea Life Sciences Holdings Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings Price-to-Operating-Cash-Flow Chart
|
Panacea Life Sciences Holdings Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
- |
- |
- |
- |
|
Panacea Life Sciences Holdings Quarterly Data
|
|
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow falls into.
Panacea Life Sciences Holdings Price-to-Operating-Cash-Flow Calculation
Panacea Life Sciences Holdings's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.14839 | / | -0.093 |
| = | |
Panacea Life Sciences Holdings's Share Price of today is $0.14839.
Panacea Life Sciences Holdings's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Business Description
Traded in Other Exchanges
N/A
Address
5910 S University Boulevard, C18-193, Greenwood Village, CO, USA, 80121
Panacea Life Sciences Holdings Inc is a cannabinoid nutraceutical manufacturer and research company that produces natural pharmaceutical alternatives for consumers and pets. It manufactures and sells soft gels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals.
Executives
| Leslie Buttorff |
director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER |
16194 W 45TH DRIVE, GOLDEN CO 80403 |
| Janice Nerger |
director |
5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121 |
| Nathan Joel Berman |
officer: CONTROLLER & PRIN ACTNG OFCR |
16194 W 45TH DRIVE, GOLDEN CO 80403 |
| 22nd Century Group, Inc. |
10 percent owner |
8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221 |
| Harvey J Kesner |
10 percent owner |
65 E. 55TH STREET, NEW YORK NY 10022 |
| Lawrence Wert |
director |
170 NUTTALL RD, RIVERSIDE IL 60546 |
| Chesne Derek Du |
officer: Chief Growth Officer |
80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483 |
| Alvaro Daniel Alberttis |
director |
80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483 |
| Vladislav Yampolsky |
director, 10 percent owner |
332 PLAZA REAL, BOCA RATON FL 33432 |
| Steven A Schwartz |
director |
332 PLAZA REAL, BOCA RATON FL 33432 |
| Andrew L. Johnson |
officer: Chief Strategy Officer |
80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483 |
| Emiliano Angel Aloi |
officer: President |
510 SUNSHINE DRIVE, DELRAY BEACH FL 33444 |
| Jonathan Gilbert |
director, officer: Executive Chairman |
36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577 |
| John C Price |
director |
4721 IRONTON STREET, BUILDING A, DENVER CO 80239 |
| Kevin James Esval |
director |
NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019 |
Panacea Life Sciences Holdings (Panacea Life Sciences Holdings) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PLSH has been successfully added to your